Literature DB >> 31318840

A Dried Blood Spot Analysis for Solithromycin in Adolescents, Children, and Infants: A Short Communication.

Ryan J Beechinor1, Michael Cohen-Wolkowiez2,3, Theresa Jasion3, Christoph P Hornik2,3, Jason E Lang2, Robert Hernandez4, Daniel Gonzalez1.   

Abstract

BACKGROUND: Solithromycin is a fourth-generation macrolide antibiotic with potential efficacy in pediatric community-acquired bacterial pneumonia. Pharmacokinetic (PK) studies of solithromycin in pediatric subjects are limited, therefore application of minimally invasive drug sampling techniques, such as dried blood spots (DBS), may enhance the enrollment of children in PK studies. The objectives of this study were to compare solithromycin concentrations in DBS with those in liquid plasma samples (LPS) and to quantify the effects of modeling DBS concentrations on the results of a population PK model.
METHODS: Comparability analysis was performed on matched DBS and LPS solithromycin concentrations collected from two different phase 1 clinical trials of solithromycin treatment in children (clinicaltrials.gov #NCT01966055 and #NCT02268279). Comparability of solithromycin concentrations was evaluated based on DBS:LPS ratio, median percentage prediction error, and median absolute percentage prediction error. The effect of correcting DBS concentrations for both hematocrit and protein binding was investigated. In addition, a previously published population PK model (NONMEM) was leveraged to compare parameter estimates resulting from either DBS or LPS concentrations.
RESULTS: A total of 672 paired DBS-LPS concentrations were available from 95 subjects (age: 0-17 years of age). The median (range) LPS and DBS solithromycin concentrations were 0.3 (0.01-12) mcg/mL and 0.32 (0.01-14) mcg/mL, respectively. Median percentage prediction error and median absolute percentage prediction error of raw DBS to LPS solithromycin concentrations were 5.26% and 22.95%, respectively. In addition, the majority of population PK parameter estimates resulting from modeling DBS concentrations were within 15% of those obtained from modeling LPS concentrations.
CONCLUSIONS: Solithromycin concentrations in DBS were similar to those measured in LPS and did not require correction for hematocrit or protein binding.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31318840      PMCID: PMC6856424          DOI: 10.1097/FTD.0000000000000670

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.118


  18 in total

Review 1.  Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls.

Authors:  Peter M Edelbroek; Jacques van der Heijden; Leo M L Stolk
Journal:  Ther Drug Monit       Date:  2009-06       Impact factor: 3.681

2.  Implementing dried blood spot sampling for clinical pharmacokinetic determinations: considerations from the IQ Consortium Microsampling Working Group.

Authors:  Christopher Evans; Mark Arnold; Peter Bryan; Jeffrey Duggan; Christopher A James; Wenkui Li; Steve Lowes; Luca Matassa; Timothy Olah; Philip Timmerman; Xiaomin Wang; Enaksha Wickremsinhe; John Williams; Eric Woolf; Patricia Zane
Journal:  AAPS J       Date:  2014-12-09       Impact factor: 4.009

Review 3.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

4.  Some suggestions for measuring predictive performance.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

5.  SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.

Authors:  Thomas M File; Barbara Rewerska; Violeta Vucinic-Mihailovic; Joven Roque V Gonong; Anita F Das; Kara Keedy; David Taylor; Amanda Sheets; Prabhavathi Fernandes; David Oldach; Brian D Jamieson
Journal:  Clin Infect Dis       Date:  2016-07-22       Impact factor: 9.079

Review 6.  Therapeutic drug monitoring by dried blood spot: progress to date and future directions.

Authors:  Abraham J Wilhelm; Jeroen C G den Burger; Eleonora L Swart
Journal:  Clin Pharmacokinet       Date:  2014-11       Impact factor: 6.447

7.  Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents.

Authors:  Daniel Gonzalez; Laura P James; Amira Al-Uzri; Miroslava Bosheva; Felice C Adler-Shohet; Susan R Mendley; John S Bradley; Claudia Espinosa; Eva Tsonkova; Kathryn Moffett; Lucila Marquez; Kari A Simonsen; Stefan Stoilov; Felix Boakye-Agyeman; Theresa Jasion; Christoph P Hornik; Robert Hernandez; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 8.  Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy.

Authors:  Bryan J Donald; Salim Surani; Harmeet S Deol; Uche J Mbadugha; George Udeani
Journal:  Drug Des Devel Ther       Date:  2017-12-13       Impact factor: 4.162

9.  Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents.

Authors:  Daniel Gonzalez; Debra L Palazzi; Leena Bhattacharya-Mithal; Amira Al-Uzri; Laura P James; John Bradley; Natalie Neu; Theresa Jasion; Christoph P Hornik; P Brian Smith; Daniel K Benjamin; Kara Keedy; Prabhavathi Fernandes; Michael Cohen-Wolkowiez
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.938

10.  Applications and Diagnostic Potential of Dried Blood Spots.

Authors:  Kapil Gupta; Rajiv Mahajan
Journal:  Int J Appl Basic Med Res       Date:  2018 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.